This study is undertaken to design a novel nano-sized delivery system of tissue-type
plasminogen activator (t-PA) which has a suppressed thrombolytic activity of t-PA, but …

Background: Clinical efficacy of thrombolytic drugs is limited by lack of specific delivery and
requires large therapeutic doses which increase toxicity. Encapsulating these drugs in …

Due to the high morbidity and mortality of cardiovascular diseases, there is an urgent need
for research on antithrombotic strategies. In view of the short half-life, insufficient drug …

Essentials• Vessel stenosis due to large thrombus formation increases local shear 1‐2
orders of magnitude.• High shear at stenotic sites was exploited to trigger eptifibatide …

Conventional thrombolytic therapy of ischemic stroke by tPA shows sometimes
complications or insufficient therapeutic effects due to limitations of tPA. To prolong the …

Local drug delivery has become an important treatment modality for the prevention of
thrombotic events following coronary angioplasty. In this study, we investigate the ability of …

Systemic thrombolytic drug administration has always gained an unideal therapeutic effect
due to the rapid neutralization by its antidotes. It is significant to seek an approach for …

Occlusive thrombosis is a central pathological event in heart attack, stroke,
thromboembolism, etc. Therefore, pharmacological thrombolysis or anticoagulation is used …

Tissue plasminogen activator (tPA) is the sole approved therapeutic molecule for the
treatment of acute ischemic stroke. Yet, only a small percentage of patients could benefit …

Platelet transfusion is used for treating a variety of bleeding complications. Natural platelet-
based transfusion products have very short storage life (3–7 days) and high risks of …